Hubert L. Allen's most recent trade in Abbott Laboratories was a trade of 8,382 Common shares without par value done at an average price of $135.9 . Disclosure was reported to the exchange on Feb. 28, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT, GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 135.87 per share. | 28 Feb 2025 | 8,382 | 191,899 (0%) | 0% | 135.9 | 1,138,862 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 57,635 | 57,635 | - | - | Option (right to buy) | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 15,475 | 200,281 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 131,360 | 58,428 | - | - | Option (right to buy) | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 29 Jan 2025 | 131,360 | 316,166 (0%) | 0% | 38.4 | 5,044,224 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 128.35 per share. | 29 Jan 2025 | 131,360 | 184,806 (0%) | 0% | 128.3 | 16,859,675 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 29 Jan 2025 | 58,428 | 243,234 (0%) | 0% | 38.4 | 2,243,635 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 128.07 per share. | 29 Jan 2025 | 58,428 | 184,806 (0%) | 0% | 128.1 | 7,482,629 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 58,428 | 0 | - | - | Option (right to buy) | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 21 Oct 2024 | 157,421 | 342,227 (0%) | 0% | 47 | 7,398,787 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2024 | 157,421 | 0 | - | - | Option (right to buy) | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 116.98 per share. | 21 Oct 2024 | 150,271 | 184,806 (0%) | 0% | 117.0 | 17,578,702 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 118.15 per share. | 21 Oct 2024 | 5,901 | 335,077 (0%) | 0% | 118.1 | 697,203 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 118.81 per share. | 21 Oct 2024 | 1,249 | 340,978 (0%) | 0% | 118.8 | 148,394 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.05 per share. | 29 Feb 2024 | 8,214 | 185,659 (0%) | 0% | 120.1 | 986,091 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 118.50 per share. | 29 Feb 2024 | 853 | 184,806 (0%) | 0% | 118.5 | 101,081 | Common shares without par value |
Abbott Laboratories | Hubert Allen L. | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 67,318 | 67,318 | - | - | Option (right to buy) | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 17,914 | 193,873 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.77 per share. | 28 Feb 2023 | 8,515 | 177,028 (0%) | 0% | 99.8 | 849,542 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 100.70 per share. | 28 Feb 2023 | 1,069 | 175,959 (0%) | 0% | 100.7 | 107,648 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 72,754 | 72,754 | - | - | Option (right to buy) | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 18,448 | 185,543 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.41 per share. | 28 Feb 2022 | 9,878 | 168,545 (0%) | 0% | 122.4 | 1,209,166 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 118.17 per share. | 28 Feb 2022 | 1,450 | 167,095 (0%) | 0% | 118.2 | 171,348 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 95,000 | 95,000 | - | - | Option (right to buy) | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 20,385 | 178,423 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.58 per share. | 26 Feb 2021 | 10,913 | 158,038 (0%) | 0% | 121.6 | 1,326,803 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 87,422 | 87,422 | - | - | Option (right to buy) | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 17,055 | 168,951 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 123.47 per share. | 01 Feb 2021 | 201,343 | 153,946 (0%) | 0% | 123.5 | 24,858,995 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 107,793 | 0 | - | - | Option (right to buy) | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.12 per share. | 01 Feb 2021 | 107,793 | 259,689 (0%) | 0% | 39.1 | 4,216,862 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 95,600 | 189,788 | - | - | Option (right to buy) | |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 01 Feb 2021 | 95,600 | 355,289 (0%) | 0% | 38.4 | 3,671,040 | Common shares without par value |
Abbott Laboratories | Hubert L. Allen | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 124.03 per share. | 01 Feb 2021 | 2,050 | 151,896 (0%) | 0% | 124.0 | 254,257 | Common shares without par value |